Abstract: The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.

Abstract: Provided among other things is a method of treating a diseased tissue that is a cancer tissue, virally infected tissue, or a tissue infected with an obligate intracellular parasite, in a large animal comprising: (a) administering a therapeutic agent effective for treating the disease to the animal; and (2) using over a period of time one or more phased arrays of antennas to direct pulses of radio frequency or microwave radiation in permeability-enhancing amount to the affected tissue, wherein the pulsed radiation is effective to promote the activity of the therapeutic agent against cells of the cancerous tissue or against the activity of the pathogen.

Abstract: Novel photocleavable drug conjugates for forming drug depots comprise drugs attached to photocleavable groups. The drug is crosslinked via photocleavable group(s) to themselves to form a photocleavable drug conjugate that generally forms the depot.

Abstract: Aspects of the disclosure include devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering vectors to target cells. The subject systems include light-activated proteins, response proteins, nucleic acids comprising nucleotide sequences encoding these proteins, as well as expression systems that facilitate expression of these proteins in target cells. Also provided are methods of using the subject devices and systems to optogenetically inhibit and intercept action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or non-human animal subject.

Abstract: A periodontal structure regeneration composition for treatment of periodontal disease is a mixture of particles of a bone growth material and free collagen. All particles are sized to be less than 1 mm in diameter. The periodontal regeneration composition is injected into the periodontal pocket through an 18 gauge needle. The composition may contain a thickener that increases the viscosity of the composition after the material has been injected into the periodontal pocket. The composition is available in pre-filled syringes offered in a kit that may also contain strips of surgical sponge or gauze that are sized to fit within a periodontal pocket, a time of adhesive, a dental bur, a probe, a gauze placement tool, gauze counter and a brush for cleaning the dental bur.

Abstract: A glucosamine peptide compound or a pharmaceutically acceptable salt thereof are useful for treating liver metabolic disorders, wherein the glucosamine peptide compound may have the structure of Glc-L-Pep, and wherein Glc represents glucosamine moiety, L represents a linker, Pep represents a peptide moiety consisting of two to six amino acid residues, Glc and L are bonded by an ether linkage, and L and Pep are bonded by an amide linkage. The liver metabolic disorders include nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcoholic fatty liver disease, alcoholic steatohepatitis, hepatic steatosis, liver fibrosis, cirrhosis or a combination thereof.

Abstract: Provided herein are branched poly(beta-amino esters) (PBAE) useful as vehicles for the delivery of therapeutic agents, such as nucleic acids. The disclosed polymers form stable compositions, and are suitable for the delivery of therapeutic agents via nebulization. Compositions of the disclosed polymers are capable of delivering therapeutic agents such as mRNA to lung epithelial cells.

Abstract: Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.

Abstract: A nucleic acid film fabrication method, includes: a mixing step in which a nucleic acid is added in powder form to distilled water or deionized water to prepare a mixed solution; a stirring step in which the mixed solution is stirred; a mixed solution application step in which the mixed solution is applied to a mold corresponding in shape to a final product of a nucleic acid film; and a drying step in which the mixed solution applied to the mold is dried to be formed into the nucleic acid film, wherein the mold has a groove formed thereon in a thickness direction thereof, such that the nucleic acid film passing through the drying step has a protrusion protruding from one surface thereof toward human skin to correspond to the groove.

Abstract: The first aspect of the present invention relates to an ophthalmic composition comprising (A) one or more kinds selected from the group consisting of terpenoid, a tocopherol, and a benzyl ammonium compound and a salt thereof, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin. The second aspect of the present invention relates to an ophthalmic composition comprising (A2) a surface active component and (B2) a buffer, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.

Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.

Abstract: The disclosure relates to, among other things, pharmaceutical compositions, such as solid oral dosage forms, comprising itraconazole, methods of making the compositions, and methods of using the same for treating disorders including, but not limited to, fungal infections.

Abstract: A topical composition and methods of making the composition is disclosed. The composition may comprise an ointment base, C11-C40 alcohols or acids, and a polymer. The ointment base may be in an amount of at least about 50% of the topical composition by weight. The polymer may be substantially soluble in the ointment base.

Abstract: A liquid composition comprising: a primary component being an Active Pharmaceutical Ingredient (API), a nutritional supplement, or combinations thereof: a base; and a preservative blend is provided along with a method of making said composition.

Abstract: Isatoic anhydride derivatives having an N-substituent which includes a quaternary ammonium group are useful for labeling and/or functionalizing a target material and/or for coupling materials together. The isatoic anhydride derivatives of the present disclosure can be advantageously water soluble, easily prepared and purified. Isatoic anhydride derivatives useful in the present disclosure preferably have at least one chemically reactive group or at least one binding group or at least one detectable label. Anthranilate derivatives made from the isatoic anhydrides derivatives or otherwise and kits including the isatoic anhydride derivatives are also disclosed.

Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.

Abstract: A conjugate for delivery of drugs, such as genetic drugs, (e.g., siRNA or antisense oligonucleotides (ASO) across biological membranes is provided. The conjugates of the Invention are capable of delivering drugs in both presence and absence of plasma proteins.

Abstract: Compositions and methods for stabilizing biomolecules are disclosed. Specifically, the compositions include novel homopolymers or copolymers containing trehalose side chains conjugated to biomolecules. When such homopolymers or copolymers are placed in close proximity to biomolecules, such as proteins, the homopolymers or copolymers protect and/or stabilize the biomolecule. The compositions and methods may be suitable for use in various industries such as healthcare (pharmaceuticals), molecular biology, biofuels, paper, personal care, detergent, photographic, rubber, brewing, dairy and food processing industries.

Abstract: The invention relates to inhibitory compounds of a p38 MAP kinase having a structure of type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. Pharmaceutical compositions are disclosed containing an effective amount of the substance SB203580 or one or more of the conjugated compounds of type (I)-(VII) or a combination thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is a method for the prophylaxis and/or treatment of a disease or a condition in which there is a possibility of the formation and/or growth of adhesions, which makes it possible to dispense with the additional administration of a preparation in the post-operative period.

Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as maytansinoid attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided.

Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.

Abstract: The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections.

Abstract: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.

Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.

Abstract: A conjugate of formula (I): L-(DL)p (I) wherein L is a Ligand unit, D is a Drug Linker unit of formula (II) wherein p is an integer of from 1 to 20.

Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.

Abstract: Disclosed are particles for delivering cytokinese, such as IL-12, for the treatment of cancer. The particles comprise cytokines non-covalently bound to liposomes, where the liposomes are coated with polyelectrolytes.

Abstract: An anti-infective composition comprising glycogen or phytoglycogen nanoparticles is provided.

Abstract: The present invention relates to the field of antimicrobial agents active against Salmonella bacteria. In particular, the present invention relates to polypeptides comprising a first and a second amino acid sequence, wherein the first amino acid sequence is an endolysin, and wherein the second amino acid sequence is an antimicrobial peptide, cationic peptide, hydrophobic peptide, amphipathic peptide or sushi peptide, and wherein the polypeptide comprises at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 and derivatives thereof. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field and in the field of food and feed.

Abstract: The present invention relates to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glycoproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatment of cancer or CNS disorders.

Abstract: In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of diseases associated with a metabolic imbalance in a subject (e.g.,cancer). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-increasing agent based upon the subject's metabolic profile.

Abstract: Methods of expressing a neuropeptide in a neuron of a subject are described. ethods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.

Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.

Abstract: Systems and methods for pulsing high intensity narrow spectrum light are provided. In one example embodiment, a lighting system includes can include one or more high intensity narrow spectrum light sources configured to emit high intensity narrow spectrum light. The lighting system can further include a power circuit configured to provide power to the one or more high intensity narrow spectrum light sources and a pulsing circuit configured to control delivery of power to the one or more high intensity narrow spectrum light sources so as to pulse the emission of high intensity narrow spectrum light from the one or more high intensity narrow spectrum light sources.

Abstract: Antimicrobial backlit devices and methods are provided. In one example embodiment, a device can have an antimicrobial lighting system. The antimicrobial lighting system includes a light source associated with a display device. The light source includes a plurality of lighting elements. One or more of the lighting elements of the plurality of lighting elements can be configured to emit high intensity narrow spectrum (HINS) light proximate the display device (e.g., onto or through the display device).

Abstract: A container includes a first wall and an opposing second wall that extend between a first end and an opposing second end, a first fluid flow path being bounded between the first wall and the second wall. An inlet is formed at the first end and communicates with the first fluid flow path. An outlet is formed at the second end and communicates with the first fluid flow path. The first wall includes a primary wall portion having a first opening extending therethrough in alignment with the first fluid flow path. A secondary wall portion extends over the first opening and is secured to the primary wall portion so as to seal the first opening closed, the secondary wall portion being comprised of a film having a thickness that is less than a thickness of the primary wall portion.

Abstract: Disinfection of a surface, such as a mouthpiece of a water bottle, using ultraviolet radiation is disclosed. A cover assembly can include a cover configured to selectively enclose the surface to be disinfected, such as the mouthpiece. The cover assembly can be configured such that ultraviolet radiation can be emitted into an interior volume at least partially formed by the cover and including the surface. The cover assembly can further include a power source which provides power to one or more ultraviolet light sources that emit the ultraviolet radiation. The cover assembly can be a mouthpiece cover assembly physically separate from a container and top cover or integrated in the top cover. A container and a top cover including one or more features for improved cleanliness are also disclosed.

Abstract: A system for cleaning and sanitizing a surface using electrolyzed solutions is provided including a first container holding an electrolyzed base cleaner and a second container holding an electrolyzed acid sanitizer. A spray device is in communication with the first container and with the second container. The spray device has a spray nozzle and an actuator for effecting discharge of the electrolyzed base cleaner and the electrolyzed acid sanitizer via the spray nozzle. A controller is in communication with the actuator and configured to successively and alternately direct the discharge of the base cleaner and the acid sanitizer from the spray nozzle of the spray device upon actuation of the actuator.

Abstract: Method of emitting peroxide vapors or mixtures thereof, where the hydrogen peroxide is placed into a vessel, whereupon an initiator, catalyst or their precursor—ferrocene is added, from which the initiator or catalyst is created by reaction with peroxide or peroxide mixture.

Abstract: A convenient way to sanitize a toilet plunger after it has been used to prevent the spreading of germs and bacteria around the bathroom. This device will be used to immerse the used plunger in a sanitizing solution, before it is stored.

Abstract: The present invention relates, in some embodiments thereof, to systems, devices and methods for decontaminating a surface of one or more vessels. In some embodiments, the systems and devices of the invention include a housing, and a wiping member disposed within the housing being configured to move across the housing, and at least one safety mechanism, thereby establishing a contaminant-free fluid passageway between vessels.

Abstract: A cartridge for use with a process monitoring system. The process monitoring system can include an adapter comprising a first fluid pathway and configured to be positioned in fluid communication with a reprocessing system. At least a portion of the cartridge can be configured to be removably received in a receptacle of the adapter. The cartridge can include a second fluid pathway configured to be positioned in fluid communication with the first fluid pathway of the adapter when at least a portion of the cartridge is positioned in the receptacle of the adapter. The cartridge can further include at least one indicator positioned on the cartridge in fluid communication with the second fluid pathway of the cartridge.

Abstract: The present invention relates to a solid pressed air freshener and odor neutralizer composition which can include greater than 10% fragrance. The air freshener comprises a fragrance; preferably the fragrance is impregnated within a water soluble substrate made from a foamed vegetable starch, a surfactant and a solidifier. The solid formulations break down easily in the presence of water and may be sprayed, within the area to be freshened.

Abstract: Gas-permeable devices which absorb VOC and pollutants and/or are biocidal, containing molded parts or consisting of molded parts, containing materials or consisting of materials on the basis of wood, biodegradable fibers, biodegradable films and/or separated manure, containing geometrically regular and/or irregular, free and/or aggregated and/or agglomerated carbon nanoparticles, carbon microparticles and/or carbon macroparticles. Carbon is selected from the group consisting of biocarbons, biochar, charcoal, screening residues of charcoal, wood ash, activated carbons, hard coal, animal charcoal, carbons from animal waste, pyrogenic carbon having different degrees of pyrolysis, functionalized carbons, pretreated carbons, washed carbons, and extracted carbons.

Abstract: Some implementations of the present invention relate to systems and methods for diffusing scents to a given location by placing a scent reservoir within a vessel including an inner chamber, a vent, and a selectively closable opening. In some cases, the scent reservoir is secured within the vessel while allowing the desired aroma to diffuse into the surrounding area through the vent. In some cases, the inner chamber comprises a wall or layer that is less permeable to the scent than is the vent. Accordingly, in some cases, the inner chamber is configured to direct the scent from the scent reservoir to the vent, which is disposed at an outer surface of the vessel. While the vessel can be any suitable object, in some cases, it is a stuffed animal. Other implementations are also described.

Abstract: A scent dispenser/absorber includes a pair of cylindrical housing members arranged coaxially about a common longitudinal axis such that the inner housing member is rotatably received in an interior chamber of the outer housing member. Each housing member has a peripheral sidewall provided with a set of radially extending apertures. A scent cartridge is removably disposed within an interior chamber of the inner housing member to absorb undesirable odors, or to emit desirable scents. By manually controlling the relative rotational positions of the housing members, a user can align or misalign the two sets of apertures, thereby enabling or disabling the transfer of scents or odors between the scent cartridge and the surrounding environment.

Abstract: An air cleaner includes: a body formed with an air suction hole defined on a side of the body, and allowing air to be introduced into the body therethrough; a metal casing into which an upper section of the body is inserted from below; a flow creation mechanism disposed inside the casing to create an air flow into and through the air cleaner; a filter disposed in the body between the air suction hole and the flow creation mechanism configured to purify air; a capacitive switch partially exposed outside the casing through a switch exposure hole defined through the casing; and a printed circuit board (PCB) disposed between one side wall of the upper section of the body and an inner wall of the casing.